Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - Proteonomix Inc. (PROT-OTC: BB) |
|
|
I believe that most investors should be aware of the synergy that exists between our subsidiaries. For example, our R&D in our subsidiary National Stem Cell Inc., utilized material from our other subsidiary SBNY to develop products for our Proteoderm subsidiary. What we would like to express to potential investors is the fact that when you invest in Proteonomix you really invest in several companies that are leading the way into the age of cellular medicine... - Michael Cohen (PROT) (Interview published August 22, 2010) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Proteonomix
(PROT) Announces Critical Patent Filing MOUNTAINSIDE, NJ, Oct 08, 2010 (MARKETWIRE via COMTEX News Network) -- Proteonomix, Inc. (OTCBB: PROT) ("Proteonomix" or the "Company") announced today that it has filed a utility patent application for the Preparation and Use of Stromal Cells for Treatment of Cardiac Diseases. Michael Cohen, President of Proteonomix, stated: "This is another step in the development of our intellectual property and getting StromaCel into the commercial market. The technology covered by the patent application will reduce the cost to the patient of this type of treatment and when trials are completed and regulatory approvals are obtained we believe that the stromal cell technology we announce today will have major importance in the treatment of cardiac damage caused by heart attacks." Without going into proprietary details, Mr. Cohen noted that the application relates to cell line expansion that he believes represents a fundamental improvement in the efficiency of producing stem cells which should have applications far beyond the cardiac therapy to which the present application relates. About Proteonomix, Inc.: Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/. Certain statements contained herein are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that the statements made in this press release constitute forward-looking statements and makes no guarantees of future performance and actual results or developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at time the statements are made. Contact: Michael Cohen Proteonomix, Inc. (973) 544-6116 SOURCE: Proteonomix
|
|
